Non-Invasive Assessment of Wound Healing With Optical Methods

NCT ID: NCT00578604

Last Updated: 2017-03-30

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

38 participants

Study Classification

OBSERVATIONAL

Study Start Date

2007-09-30

Study Completion Date

2014-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The objective of this project is to further the development of a non-invasive optically based NIR (Near Infrared) device to enable the quantitative diagnosis, monitoring and treatment optimization of chronic wounds (especially diabetic) in a clinical setting. The end goal of this project is a portable and compact device that would be simple to operate by minimally trained health care personnel. Our animal studies have shown that the early healing of chronic wounds can be characterized by absorption and scattering of light at near infrared wavelengths ranging from 680 nm to 950 nm. If our project is successful we will be providing the clinician the ability to predict if a wound is healing and if a particular treatment is successful in accelerating healing before any changes are observed by wound size contraction or other visible clinical signs. Our hope is that the fNIR optical device will provide conclusive therapeutic treatment information as early as 5 weeks after initial evaluation, before it would be obvious on gross examination of the patient.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Diabetic Foot Ulcers

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Patients with a diabetic wound

Patients with a diabetic wound

diffuse near infrared spectroscopy measurements

Intervention Type DEVICE

Measure blood flow to diabetic wounds

Control

Patients without a diabetic wound

diffuse near infrared spectroscopy measurements

Intervention Type DEVICE

Measure blood flow to diabetic wounds

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

diffuse near infrared spectroscopy measurements

Measure blood flow to diabetic wounds

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Subjects must be 18-65 years of age
* Subjects must have no history of diabetes
* Subjects must have no history of vascular disease
* Subjects must have no findings of vascular disease on physical examination
* Subjects who are not allergic to Tegaderm


* Subjects must be 18-65 years of age
* Subjects must have documented diabetes mellitus for at least 6 months.
* Subjects must have at least one documented chronic wound for a minimum 8 weeks.
* A chronic wound is defined as any wound that has not healed after 8 weeks and has a minimum surface area of 1cm2. There is no maximum wound size.
* Wound(s) must be secondary to the complications of diabetes, including vascular disease neuropathy, or both.
* Wounds must be on the ankles or feet
* Subjects who are not allergic to Tegaderm

Exclusion Criteria

* Subject must not be \<18 or \>65 years of age
* Subjects with major infections, abscesses, or untreated osteomyelitis will be excluded until appropriately treated.
* Subjects will not be excluded based upon the existence of other co-morbidities associated with chronic diabetes, including retinopathy, nephropathy, peripheral neuropathy, or cardiovascular disease except as follows:
* Subjects who have moderate to severe vascular insufficiency (defined as ankle brachial index \<0.75 or toe-brachial index \<0.5)
* Subjects who are unable to return for weekly follow-up appointments will not be included.
* Pregnant or lactating people will not be invited to participate.
* Subjects who are allergic to Tegaderm
Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Drexel University College of Medicine

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Michael S Weingarten, M.D.

Role: PRINCIPAL_INVESTIGATOR

Drexel University College of Medicine

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Drexel University College of Medicine Wound Care Center

Philadelphia, Pennsylvania, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

17035

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Diabetic Foot Ulcer Imaging- Study 2
NCT03942081 RECRUITING NA
Photoacoustic Imaging of Foot Wound
NCT07216599 RECRUITING NA